Zacks Investment Management »

Lineage Cell Therapeutics In shares owned by Zacks Investment Management

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by Zacks Investment Management from 13F filings

Historical chart of Zacks Investment Management investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by Zacks Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by Zacks Investment Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $55k 42k 1.31
2025-03-31 $21k 46k 0.45

More positions owned by Zacks Investment Management

Apple (AAPL)
NVIDIA Corporation (NVDA)
Alphabet Cap Stk Cl A (GOOGL)
Microsoft Corporation (MSFT)
Broadcom (AVGO)
Caterpillar (CAT)
JPMorgan Chase & Co. (JPM)
Amazon (AMZN)
Wal-Mart Stores (WMT)
Meta Platforms Cl A (META)
Johnson & Johnson (JNJ)
Cisco Systems (CSCO)
Abbvie (ABBV)
Parker-Hannifin Corporation (PH)
Exxon Mobil Corporation (XOM)

View all positions for Zacks Investment Management

Top funds holding Lineage Cell Therapeutics In

Broadwood Capital
BlackRock
Vanguard Capital Management
Defender Capital
Geode Capital Management
Raffles Associates
Fifth Third Bancorp
Millennium Management
Morgan Stanley
Vanguard Fiduciary Trust
Northern Trust
Renaissance Technologies
Marshall Wace
Vanguard Portfolio Management
State Street Corporation

View all funds holding Lineage Cell Therapeutics In